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Minimally differentiated acute myeloid leukemia (AML-M0) is a rare subtype of AML with poor prognosis. Although
genetic alterations are increasingly reported in AML, the gene mutations have not been comprehensively studied
in AML-M0. We aimed to examine a wide spectrum of gene mutations in patients with AML-M0 to determine their
clinical relevance. Twenty gene mutations including class I, class II, class III of epigenetic regulators (IDH1, IDH2,
TET2, DNMT3A, MLL-PTD, ASXL1, and EZH2), and class IV (tumor suppressor genes) were analyzed in 67 patients
with AML-M0. Mutational analysis was performed with polymerase chain reaction–based assays followed by
direct sequencing. The most frequent gene mutations from our data were FLT3-ITD/FLT3-TKD (28.4%), followed by
mutations in IDH1/IDH2 (28.8%), RUNX1 (23.9%), N-RAS/K-RAS (12.3%), TET2 (8.2%), DNMT3A (8.1%), MLL-PTD
(7.8%), and ASXL1 (6.3%). Seventy-nine percent (53/67) of patients had at least one gene mutation. Class I genes
(49.3%) were the most common mutated genes, which were mutually exclusive. Class III genes of epigenetic
regulators were also frequent (43.9%). In multivariate analysis, old age [hazard ratio (HR) 1.029, 95% confidence
interval (CI) 1.013-1.044, P = .001) was the independent adverse factor for overall survival, and RUNX1 mutation
(HR 2.326, 95% CI 0.978-5.533, P = .056) had a trend toward inferior survival. In conclusion, our study showed a
high frequency of FLT3, RUNX1, and IDH mutations in AML-M0, suggesting that these mutations played a role in
the pathogenesis and served as potential therapeutic targets in this rare and unfavorable subtype of AML.
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Minimally differentiated acute myeloid leukemia (AML-M0) accounts
for approximately 2% to 5% of all AMLs according to the French-
American-British classification [1]. It frequently occurs in elderly
patients and confers a poor prognosis [2]. Morphologically, the
leukemic cells are large and agranular blasts mimicking lymphoblasts
and negative for cytochemical reactions of myeloperoxidase (MPO),
Sudan Black B, or nonspecific esterase [1]. The immunophenotypic
characteristics of AML-M0 blasts are low expression of MPO, positive
for at least one myeloid antigen (CD13, CD33, CD15, or CD11b),
frequent expression of stem cell–associated antigens (CD34, HLA-DR,
CD117), TdT, and occasional coexpression of lymphoid-associated
antigens (CD7 or CD19) [1,3]. As for cytogenetic abnormalities,
despite that the incidence of abnormal, complex, or unbalancedchromosomal changes has been reported to be more frequent, there are
no recurrent or specific cytogenetic abnormalities in AML-M0 [3]. In
AML, gene mutations not only have an implication in molecular
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cytogenetic subtypes [4].
Previous studies have focused on class I and class II mutations in
AML-M0 [5–8]. The development of AML was oftentimes caused
by at least two-hit process mostly by class I and class II mutations.
The class I mutation is defined by activating mutations of receptor
tyrosine kinases and RAS signaling pathways, and the class II
mutation is loss-of-function mutations of hematopoietic transcrip-
tion factors [9]. RUNX1 mutation was the most common gene
mutation described in AML-M0 [5]. FLT3 mutation was also
reported as a recurrent gene mutation, whereas RAS and PTPN11
mutations were less frequent in AML-M0 [6–8]. Other gene
mutations with prognostic relevance have not been studied
comprehensively in AML-M0, including mutated genes of
epigenetic regulators, such as IDH1, IDH2, TET2, DNMT3A,
ASXL1, and EZH2 genes [10–13].
We thus examined a wide spectrum of gene mutations, including
class I genes of activated signaling pathways (FLT3-ITD, FLT3-TKD,
C-FMS, KIT, N-RAS, K-RAS, PTPN11, and JAK2V617F), class II genes
affecting hematopoietic transcription and differentiation (RUNX1,
NPM1, and CEBPα), class III genes of epigenetic regulators (IDH1,
IDH2, TET2, DNMT3A, MLL-PTD, ASXL1, and EZH2), and class
IV genes of tumor suppressors (WT1 andTP53) from the bonemarrow
cells of patients with AML-M0 at the initial diagnosis. The status of
gene mutations was also correlated with the clinicohematological
features to determine their clinical relevance in patients with AML-M0.Materials and Methods
Patients and Materials
From 1991 to 2010, a total of 67 patients fulfilling the diagnostic
criteria of de novo AML-M0 at Chang Gung Memorial Hospital and
Mackay Memorial Hospital was enrolled. The diagnosis of AML-M0
was made according to the French-American-British criteria: N30%
blasts in bone marrow, b3% of blasts positive for MPO or Sudan Black
B, and expression of at least one myeloid antigen [1]. Patients with
leukemia blasts expressing specific lymphoid markers (cytoCD3,
cytoCD79a, or cytoCD22) were excluded in this study. G-banding
method was used for karyotypic analysis, and results were interpreted
according to the International System for Human Cytogenetic
Nomenclature. Cytogenetic categorization of favorable-, intermediate-,
and adverse-risk groups was accorded to the criteria recommended by
European LeukemiaNet (ELN) Guidelines [4]. A panel of monoclonal
antibodies including myeloid-associated antigens (CD13, CD33,
CD11b, CD14, CD15, and/or CD41a), lymphoid-associated antigens
(CD7, CD19, cytoCD3, and cytoCD22 or cytoCD79a if necessary), as
well as lineage-nonspecific antigens (CD34, CD117, HLA-DR, TdT,
or CD56) was used to determine the immunophenotypes of leukemia
cells. The study was approved by the Institutional Review Boards of
Chang Gung Memorial Hospital and Mackay Memorial Hospital.Cell Fractionation
The mononuclear cells were obtained from bone marrow samples
by Ficoll-Hypaque density gradient centrifugation (1.077 g/ml;
Amersham Pharmacia, Buckinghamshire, United Kingdom).
The mononuclear cells were then cryopreserved in medium
containing 10% DMSO and 20% FBS at −70°C or in liquid
nitrogen until test.DNA, RNA Extraction, and cDNA Preparation
Genomic DNA was extracted from frozen mononuclear cells of
bone marrow samples by using the QIAamp DNA mini kit (Qiagen
GmbH, Hilden, Germany) following the manufacturer’s instruc-
tions. The TRIzol Reagent (Life Technology, Carlsbad, CA) was used
to extract RNA that was reversely transcribed to cDNA with the
Superscript II RNase H2 reverse transcriptase kit (Invitrogen
Corporation, Carlsbad, CA).
Detection of Gene Mutations
FLT3-ITD, FLT3-TKD, KIT, C-FMS, K-RAS, N-RAS, JAKV617F,
PTPN11, RUNX1, CEBPα, NPM1, TP53, WT1, IDH1, IDH2,
TET2, DNMT3A, MLL-PTD, ASXL1, and EZH2 mutations were
analyzed. The genomic DNA–polymerase chain reaction or reverse
transcription–polymerase chain reaction assays followed by direct
sequencing were used to detect FLT3-ITD [14], point mutations at
tyrosine kinase domain of FLT3 (FLT3-TKD) [15], KIT and C-FMS
mutations [16], point mutations at codons 12, 13, and 61 in exons 1
and 2 of N-RAS and K-RAS genes [17], exons 3 to 8 of RUNX1
mutations [18], CEBPα mutations [19], MLL-PTD [20], PTPN11,
TET2, IDH1, IDH2, DNMT3A, and ASXL1 [21] as previously
described. The detection of mutated genes in TP53, exons 1 to 3 and
exons 7 to 9 of WT-1, JAK2V617F, and NPM1 was performed
according to the previously reportedmethods of other investigators with
some modification [22–25]. The detection of EZH2 mutation was
carried out using a self-designed and/or previously reported method,
which was described in detail in the Supplementary Materials (Tables
W1–W3 and Figure W1).
Statistical Analysis
Fisher exact test, χ2 analysis, and Wilcoxon rank-sum test were
used whenever appropriate to make comparisons between groups.
Estimates of survival were calculated according to the Kaplan-Meier
method. Comparisons of estimated survival curves were analyzed by
the log-rank test. For multivariate analysis, a Cox regression model
was used to identify prognostic variables. Variables with P values of .2
or less in univariate analysis were included in the model. In all
analysis, the P values were two-sided and considered statistically
significant when values were lower than .05. Statistical analysis was
carried out by SPSS version 17.0 (SPSS Inc, Chicago, IL).Results
Patient Characteristics
The baseline characteristics of the 67 patients with AML-M0 are
listed in the Supplemental Materials (Table W4). The median age was
49.0 years (range 0.3-97.9 years). Twenty-two of the 67 (32.8%)
patients were female. The estimated median overall survival (OS) was
5.1 months (Figure W2A). Thirty-nine patients received standard
AML induction protocol (60 mg/m2 daunomycin for 3 days and
150 mg/m2 cytarabine for 7 days for adults and TPOG-AML97A for
children with an age younger than 18 years) [26]. Six patients
(age 64.3-81.2 years) received low dose therapy including low dose
cytarabine, hydroxyurea, or melphalan. Seventeen patients with a
median age of 73.1 years old received supportive care only. Five
(7.5%) patients were treated as acute lymphoblastic leukemia. Of the
39 patients who received standard AML therapy, 7 had early death
during the induction therapy and 29 achieved complete remission yet
with a relapse rate of 72.4% (21/29). Three patients from those who
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after second complete remission. The median OS of the 39 patients
who received chemotherapy was 11.1 months (Figure W2B).
The median follow-up time for this cohort was 4.8 months (range
0-176.6 months). Fifty-nine patients died and eight were still alive.
Frequency and Types of Mutations in AML-M0
Of the 67 patients with de novo AML-M0, 79.1% (53/67) patients
were found to have at least one gene mutation among the genes
examined. The diagram of the gene mutation status in patients with
AML-M0 is illustrated in Figure 1. The pairwise cooperativeness
between gene mutations is depicted in Figure 2.
Class I mutations. FLT3-ITD mutations were detected in
22.4% (15/67) and FLT3-TKD in 6.0% (4/67) patients. RAS
mutations were present in 12.3% (8/65) patients, with three K-RAS
and five N-RAS mutations. The frequency of PTPN11, C-FMS,
and JAK2V617F mutations were 6.2% (4/65), 1.8% (1/56), and
1.6% (1/64), respectively. None had KIT mutation.
Class II mutation. A total of 17 RUNX1 mutations was detected
in 23.9% (16/67) patients, including two nonsense mutations, seven
frameshift, seven missense mutations, and one insertion mutation.
One patient had CEBPα and NPM1 mutations each.
Class IIImutations. IDHmutations were present in 28.8% (19/66)
patients. All IDH mutations were missense mutations, with IDH1-
R132 in five, IDH2-R140 in five, and IDH2-R172 in nine patients.
TET2, DNMT3A, MLL-PTD, and ASXL1 mutations were detectedFigure 1. Diagram of AML-M0 patients with gene mutations. The g
groups in AML-M0 patients at the initial diagnosis are illustrated.less frequently, occurring in 8.2% (5/61), 8.1% (5/62), 7.8% (5/64),
and 6.3% (4/64) patients, respectively. EZH2mutation was detected in
only 1 of 60 patients examined.
Class IV mutations. TP53 and WT1 occurred in 7.8% (5/64)
and 4.8% (3/63) patients, respectively.
On the basis of the functional class of gene groups, 49.3% (33/67)
patients had class I mutations that were mutually exclusive, 26.9%
(18/67) had class II, 43.9% (29/66) had class III, and 12.5% (8/64)
had class IV mutations. Twenty-four patients had gene mutations
within a single class, with 12 in class I, 4 in class II, 7 in class III, and 1
in class IV.
Karyotypes and the Association with Gene Mutations
Cytogenetic data were available for 49 patients. Twenty-nine
(59.2%) patients had normal karyotypes, 7 (14.3%) patients had a
single abnormality, 3 (6.1%) patients had two abnormalities, and
10 (20.4%) patients had complex cytogenetic aberrations. Mono-
somal karyotypes were found in eight (16.3%) patients. Trisomy
21, trisomy 8, monosomy 8, and del(5q) were found in four, three,
three, and two patients, respectively. Only one patient with isolated
trisomy 13 had concomitant RUNX1 mutation. Thirty-eight
patients (77.6%) were in the intermediate-risk group, 11
(22.4%) patients in the unfavorable-risk group, and none had
favorable cytogenetics by the ELN criteria. All gene mutations
examined were not associated with specific ELN cytogenetic risk
groups or normal karyotypes.ene mutation status, cooperating mutations, and cytogenetic risk
Figure 2. Pairwise cooperativeness between gene mutations in AML-M0 patients. A circus diagram depicts the pairwise cooperativeness
of gene mutation in AML-M0 patients. The length of the arc represents the number of mutations in the first gene, and the width of the
ribbon represents the number of patients with a mutation in the second gene.
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Features of Patients with AML-M0
We correlated gene mutations with clinical parameters, including
age, sex, hemoglobin level, platelet counts, white blood cell counts,
percentages of circulating blasts and marrow blasts, and cytogenetic risk
groups (Table 1). RUNX1 and IDH mutations were significantlyTable 1. Clinical Characteristics of AML-M0 Patients with RUNX1, FLT3, IDH, and RAS Mutation
RUNX1 (n = 67) FLT3-ITD or FLT3-TKD (n = 6
Mutation Wild type P Mutation Wild type
Number of patients 16 51 19 48
Age (years) 68.0 (5.5-97.9) 46.7 (0.3-84.2) .011 46.7 (11.0-75.8) 54.3 (0.3-97.9
Sex (male/female) 4/12 18/33 .550 7/12 15/33
Hemoglobin (g/l) 77 (40-110) 74 (38-124) .600 68 (40-117) 77 (38-124)
Platelet (×109/l) 4.5 (0.8-13.9) 3.2 (0.1-59.8) .394 4.4 (0.8-13.5) 3.0 (0.2-59.8)
WBC (×109/l) 22.9 (1.1-187.2) 10.7 (0.6-397.8) .595 15.9 (0.6-204.6) 13.0 (0.7-379.2
Circulating blasts (%) 61.8 (0-98.2) 53.0 (0-99.3) .899 63 (1-98.0) 53.5 (0-99.3)
Marrow blasts (%) 88.4 (76.0-99.0) 90.1 (29.4-98.8) .857 91.8 (72.2-99.0) 88.5 (29.4-98.
Karyotype .708
Favorable 0 0 0 0
Intermediate 10 28 11 27
Poor 2 9 1 10
Trisomy 13 1 0 0 1
Monosomy 1 7 2 6
EFS † 1.9 (0-5.2) 2.2 (0-5.5) .133 5.3 (4.1-6.5) 1.9 (0.8-3.0)
OS † 2.6 (0-6.2) 5.3 (0-12.8) .168 15.2 (6.8-23.6) 3.0 (0.2-5.8)
Values are expressed as medians (range).
† Values are expressed as medians (95% CI).associated with older age (median 68.0 vs 46.7 years for RUNX1, P =
.011; 66.0 vs 44.1 for IDH, P = .016). Patients with MLL-PTD were
younger than those without MLL-PTD (37.0 vs 54.0, P = .044).
ASXL1 and DNMT3A mutations were associated with lower WBC
counts (2.1 × 109/l vs 15.6 × 109/l for ASXL1-mutated and wild-type,
P = .021; 2.3 × 109/l vs 15.9 × 109/l forDNMT3A-mutated and wild-s.
7) IDH1/IDH2 (n = 66) N-RAS/K-RAS (n = 65)
P Mutation Wild type P Mutation Wild type P
19 47 8 57
) .461 66.0 (5.5-84.2) 44.1 (0.3-97.9) .016 49.1 (16.0-73.5) 49.0 (0.3-97.9) .905
.660 7/12 15/32 .701 3/5 19/38 1.000
.519 75 (40-121) 75 (38-124) .756 89 (38-124) 75 (40-127) .340
.681 3.3 (0.1-19.9) 3.0 (0.2-59.8) .851 2.8 (.2-59.8) 3.3 (0.1-23.6) .761
) .761 5.4 (0.6-63.6) 15.2 (0.7-379.2) .184 31.5 (5.4-156.6) 10.7 (0.6-379.2) .123
.882 46.0(0-98.0) 55.0 (0-99.3) .817 88.0 (30.0-98.5) 49.3 (0-99.3) .012
4) .557 88.2 (43.5-95.3) 89.4 (29.4-99.0) .954 94.6 (69.2-96.0) 88.9 (29.4-99.0) .104
.252 .246 1.000
0 0 0 0
12 26 3 35
1 10 1 9
0 1 0 1
1 7 0 8
.207 1.0 (0.5-1.5) 3.0 (0-6.1) .863 1.0 (0.7-1.3) 3.0 (0-6.0) .139
.171 5.1 (0.4-9.8) 5.3 (0-13.2) .897 1.0 (0-3.1) 6.3 (0.8-11.8) .096
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of circuiting blasts (88.0% vs 49.3%, P = .012). Other gene
mutations, including FLT3 mutations, had no correlation with any
clinical features.
Outcome Analysis
We assessed the impact of cytogenetic risk group and FLT3,
IDH, RUNX1, RAS, ASXL1, DNMT3A, TET2, and MLL-PTD
mutations on OS and event-free survival (EFS; Table 2). Less
prevalent gene mutations were excluded from statistical analysis.
Cytogenetics had prognostic significance, with a median OS of
13.8 months [95% confidence interval (CI) 3.2-24.4 months] and
4.4 months (95% CI 1.6-7.2 months) for intermediate- and
unfavorable-risk groups, respectively (P = .043). The mutational
status of FLT3 (P = .171), IDH (P = .897), RUNX1 (P = .168),
RAS (P = .096), ASXL1 (P = .760), TET2 (P = .076), DNMT3A
(P = .996), or MLL-PTD (P =0.247) did not have significant
influence on OS or EFS by the log rank test (Figure W3). When the
gene mutations were categorized according to their functional class
groups, no impact on OS or EFS was observed with regard to the
functional class groups.
To assess whether the gene mutations had independent prognostic
values in patients with AML-M0 in context of other clinical and
molecular parameters, we performed multivariate analysis for FLT3,
RUNX1, RAS, TP53, and TET2 mutations adjusting for age, platelet
counts, percentage of marrow blasts, and/or ELN cytogenetic risk
groups (Table 2). The result showed that age [hazard ratio (HR)
1.029, 95% CI 1.013-1.044, P = .001] was the most significant
adverse factor for OS, and patients with RUNX1 mutation (HR
2.326, 95% CI 0.978-5.533, P = .056) had a trend toward an inferior
survival. For EFS, age (HR 1.016, 95% CI 1.000-1.033, P = .055)
was the independent unfavorable risk factor after adjusting for
cytogenetic risk group, platelet counts, RAS, MLL-PTD, TET2, and
TP53 gene mutation status.
Discussion
Previous studies reporting the clinical features or gene mutation
patterns in patients with AML-M0 were mainly from the westernTable 2. Univariate and Multivariate Analyses with Respect to EFS and OS.
EFS
Univariate Multivariate
HR 95% CI P HR 95% CI
Age 1.015 1.005-1.024 .003 1.016 1.000-1.033
Karyotype risk 1.613 0.799-3.253 .182 1.250 0.515-3.036
Platelet counts 0.976 0.941-1.012 .191 0.967 0.894-1.047
Marrow blasts (%) 1.007 0.991-1.024 .392
FLT3 mutation 0.693 0.389-1.234 .213
RUNX1 mutation 1.549 0.867-2.768 .140 2.365 0.946-5.915
IDH mutation 0.950 0.531-1.702 .864
RAS mutation 1.767 0.816-3.824 .149 2.405 0.679-8.518
MLL-PTD 0.492 0.177-1.366 .173 0.525 0.143-1.921
ASXL1 mutation 0.898 0.279-2.888 .857
DNMT3A mutation 1.375 0.425-4.442 .595
P53 mutation 2.106 0.747-5.936 .159 0.942 0.263-3.373
PTPN11 mutation 0.61 0.190-1.960 .407
TET2 mutation 0.445 0.174-1.142 .092 1.183 0.297-4.716
Class I mutation 0.797 0.481-1.320 .378
Class II mutation 1.492 0.850-2.617 .163
Class III mutation 1.063 0.639-1.769 .813
Class IV mutation 1.985 0.884-4.456 .097population and a few from the Japanese population [6]. In
this study, we examined 20 gene mutations in 67 patients with
AML-M0 from the Taiwanese ethnicity, and it showed a wider
range of gene mutations in AML-M0 compared to the western and
other Asian population. It has been described that RUNX1
mutations were common in AML-M0 with reported frequencies
ranging from 12.7% to 46% [5,6,27,28] and up to 65.4% in those
with normal karyotypes [29]. Another common mutation in
patients with AML-M0 was FLT3-ITD, with a frequency of 22%
to 29% [6,7]. We found that FLT3-ITD, RUNX1, IDH1, IDH2,
and RAS were the recurrent mutations with frequencies between
10% and 30% in our series, and our results of FLT3-ITD and
RUNX1 mutations were mostly in line with previous studies.
However, the frequency of RUNX1 mutation seemed to be slightly
higher in our cohort compared to the Japanese population (23.9%
vs 15.7%) [6]. The frequency of RAS (12.3%) and PTPN11
(6.2 %) mutations was slightly higher in our series compared with
the study of Roumier et al. [7], which showed that RAS and
PTPN11mutations occurred less frequently in patients with AML-
M0. Of note, we found a high occurrence of IDH2 (21.2%), which
has not been previously described. Other gene mutations of
epigenetic regulators including TET2, DNMT3A, MLL-PTD, and
ASXL1mutations occurred less frequently and EZH2mutation was
rare. If we took the gene functional groups into consideration,
approximately half of the patients with AML-M0 had class I gene
mutations (49.3%) and class II gene mutations involving
hematopoietic differentiation occurred in one fourth of patients,
suggesting that the receptor tyrosine kinase/RAS signaling was the
most important pathway involved in AML-M0, having FLT3
mutations being the main causal factor. Mutations of epigenetic
regulator genes (class III) detected in about 40% of patients also
played an important role in the leukemogenesis of AML-M0.
In univariate analysis, age was the most significant adverse factor
for OS and EFS. Unfavorable cytogenetic subgroup also conferred a
poor risk factor for OS.Most of the genes with high occurrence in the
present series have been reported to be poor prognostic molecular
markers in patients with AML, especially in the cytogenetically
normal group, including FLT3-ITD [30,31], IDH2 [12,32], andOS
Univariate Multivariate
P HR 95% CI P HR 95% CI P
.055 1.019 1.008-1.029 b .001 1.029 1.013-1.044 .001
.622 2.059 1.004-4.224 .049 1.735 0.712-4.227 .225
.413 0.969 0.930-1.009 .124 0.923 0.840-1.014 .093
1.015 0.997-1.033 .108 1.001 0.980-1.022 .956
0.665 0.369-1.201 .176 0.414 0.163-1.055 .065
.066 1.508 0.835-2.724 .173 2.326 0.978-5.533 .056
0.963 0.540-1.716 .897
.174 1.893 0.877-4.087 .104 1.728 0.500-5.975 .388
.300 0.553 0.199-1.536 .256
0.835 0.260-2.681 .762
1.002 0.399-2.518 .996
.927 1.762 0.693-4.481 .234
0.707 0.221-2.265 .559
.812 0.437 0.169-1.128 .087 1.308 0.314-5.441 .712
0.714 0.426-1.196 .200
1.447 0.819-2.557 .204
1.150 0.686-1.927 .595
1.712 0.804-3.645 .163
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correlation in our patients. NPM1 mutation occurred in about 50%
of AML patients with normal karyotypes and was associated with a
favorable survival [34,35]. About 60% of the patients had normal
karyotypes, but only one patient had NPM1 mutation in our study.
The poor outcome of our AML-M0 patients might be attributed
partly to the near absence of NPM1 mutation along with the high
occurrence of FLT3-ITD, which is a poor prognostic factor in
normal karyotype AML. The lack of prognostic impact of FLT3
mutations in the present study might be attributed to the limited
number of AML-M0 patients with general short survival, which avert
a confirmed conclusion. IDH2 had a higher occurrence than IDH1
in AML, but the location of IDH2 mutation was more frequent on
R140 than on R172 in the previous studies, in which M0 accounted
for less than 5% of the studied population [12,32,36–38].
Interestingly, we observed that IDH2-R172 occurred more fre-
quently than IDH2-R140 or IDH1-R132 in the present AML-M0
series. IDH2mutation on R172 has been reported to confer a poorer
outcome compared to IDH2-R140 or IDH1-R132 in AML
[36,38,39]. The number of each subtype of IDH mutants was very
small to make a meaningful statistic analysis. Findings from the
multivariate analysis showed consistency with the previous study
on that RUNX1 mutation was the poor prognostic factor for OS
and EFS [29].
Approximately half of the patients had multiple cooperating gene
mutations. More than 80% of patients harboring mutations of
epigenetic regulator genes had other coexisted gene mutations.
Although ASXL1 mutations occurred in only four patients with
AML-M0, remarkably, three of them were associated with both
RUNX1 and FLT3-ITD mutations. Likewise, all of the five patients
with MLL-PTD carried other mutated genes. Our findings
supported a multiple-hit model of leukemogenesis in AML [40].
Previous studies have shown that RUNX1 mutations frequently
coexisted with FLT3-ITD or FLT3-TKD [6], trisomy 13 (the locus
of the FLT3 gene), or FLT3 overexpression [27–29]. We found only
one patient harboring both RUNX1 mutation and trisomy 13 and
five patients with coexisting RUNX1 and FLT3-ITD mutations.
The underlying mechanism of their cooperating roles in leukemo-
genesis merits further investigation.
Most AML-M0 patients succumb to the disease despite current
standard treatment. For an aggressive AML subtype as AML-M0,
having HSCT early in the course of the disease had improved the
outcome in some small series [41,42]. We did not observe a
significantly prolonged survival in AML-M0 patients who received
HSCT in this study. The small number of patients who received
HSCT and the delayed timing for HSCT in our cohort may
effectuate the lack of significant benefit of HSCT in our patients.
Complete gene mutation profiling for AML-M0 patients at the
diagnosis may further help in identifying biologic risk factors and
potential therapeutic targets. The relevance of gene mutations in
predicting therapeutic response of myeloid malignancies to targeted
agents has not been well established. Flt3 antagonists combined with
chemotherapy or hypomethylating agents have been reported to have
impact on response rates in a phase II study [43]. Potential links
between gene mutations and the treatment responses to hypomethy-
lating agents have been reported in a few small series. Itzykson et al.
reported that patients with mutated TET2 and favorable cytogenetics
had a higher response rate to azacitidine compared to patients with
wild-type TET2 in myelodysplastic syndromes and low blast countAML [44]. Metzeler et al. reported a higher complete remission rate
in AML patients with DNMT3A mutations treated with decitabine
[45]. TET2 and/or DNMT3A mutations were found to be
independent response predictor to methyltransferase inhibitors in
patients with myelodysplastic syndrome or its related disorders [46].
However, these results have not been confirmed in randomized
clinical trials. IDH also serves as a potential therapeutic target in
AML. Chaturvedi et al. recently reported that a small molecular
inhibitor targeting mutant IDH1 induced apoptosis and decreased
colony formation in methylcellulose of IDH1-mutant human
primary bone marrow cells [47]. Our study reveals the complex
and heterogeneous molecular aberrations in AML-M0. As coexistence
of gene mutations occurs frequently, combined therapy through
multiple targeting might be the reasonable approach in future studies.
In summary, we analyzed a broad spectrum of known mutated
genes involved in myeloid neoplasms from 67 patients with de novo
AML-M0 at diagnosis. To the best of our knowledge, this is the most
comprehensive study regarding the gene mutation patterns in AML-
M0.We found that AML-M0 was characterized by high frequency of
FLT3-ITD, RUNX1, and IDH mutations. In addition to the
signaling pathway, we further demonstrated that AML-M0 was
frequently associated with mutations of epigenetic regulator genes,
occurring in more than 40% of patients. Other than old age, RUNX1
mutation was associated with a trend of inferior survival by
multivariate analysis, while FLT3, IDH, and other gene mutations
did not have impact on the outcome. Cooperation of multiple
mutations in different classes of genes was common. Our findings
suggested that AML-M0 is a complex and heterogeneous subtype of
AML in terms of molecular aberrations. The high frequency of gene
mutations in epigenetic modifiers implies that epigenetic deregula-
tion, which frequently cooperates with other gene mutations, may
play an important role in the pathogenesis of AML-M0. Further
studies on how epigenetic regulator mutations interact with mutated
genes affecting cell proliferation and/or differentiation in AML-M0
are warranted. Our findings also suggest the potential implication of
combined therapies with targeted agents in this rare and unfavorable
subtype of AML.
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